LLGL1 and cancer: Reduced expression of Hugl-1 has been detected in as many as 62% of samples in a comprehensive cohort of human solid tumors (Grifoni et al., 2004) and is associated with disease progression in cancers such as hepatocellular, colorectal, pancreatic, endometrial, as well as lung squamous cell carcinoma (Biesterfeld et al., 2012; Lu et al., 2009; Matsuzaki et al., 2015; Schimanski et al., 2005; Tsuruga et al., 2007).